Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Significant Expense Categories Reviewed By CODM (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Accounting Policies [Abstract]
License and collabortion agreement revenues	$ 0	$ 235
Research and development expenses:
Efzofitimod expenses	8,804	10,965
Preclinical development and other shared research and development expenses	2,560	2,073
Non-cash expenses (depreciation and stock-based compensation)	450	326
Total research and development expenses	11,814	13,364
General and administrative expenses:
Other general and administrative expenses	3,064	2,915
Non-cash expenses (depreciation and stock-based compensation)	895	592
Total general and administrative expenses	3,959	3,507
Other segment items	892	1,149
Consolidated net loss	$ 14,881	$ 15,487
Revenue, Product and Service [Extensible Enumeration]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]